Lixisenatide (Adlyxin): Lixisenatide is a daily injectable GLP-1 receptor agonist
Ozempic is proven to lower blood sugar and A1C along with diet and exercise Ozempic lowers the risk of major cardiovascular events such as stroke, heart attack, or death in adults who also have heart disease Ozempic lowers the risk of worsening kidney disease, kidney failure (end-stage kidney disease), and death due to cardiovascular disease, in adults who also have chronic kidney disease Ozempic may also help you lose weight a Ozempic is not a weight-loss drug a Across studies looking at A1C, adults lost on average from 7.1 lb to 14.1 lb with Ozempic
To put this in perspective, most approved migraine preventive medications reduce monthly headache days by 2 to 4 compared to placebo
Its often used for people with ongoing or chronic ischemic colitis
Research Linking Ozempic to Blindness Research continues to emerge regarding serious side effects of Ozempic and other GLP-1 receptor agonists: January 2026: Patients Who Experienced Vision Loss After Ozempic Can Make Their Case in Federal Court In December of 2025, the Joint Panel on Multidistrict Litigation chose to centralize lawsuits filed by people who took GLP-1 drugs and then were diagnosed with NAION
Providers increasingly field questions about BPC-157, making it important to understand the current evidence, the types on the market, and the regulatory landscape
